Copyright
©The Author(s) 2022.
World J Pharmacol. Nov 28, 2022; 11(3): 27-47
Published online Nov 28, 2022. doi: 10.5497/wjp.v11.i3.27
Published online Nov 28, 2022. doi: 10.5497/wjp.v11.i3.27
Table 1 Serum antioxidant status and lipid peroxidation level
Group | SOD (U/mL) | CAT (U/mL) | GSH nmol/mL | GPx IU/L | MDA μmol/L |
Control | 0.92 ± 0.02 | 23.12 ± 0.21 | 0.73 ± 0.10 | 11.68 ± 1.10 | 6.42 ± 0.02 |
SERT | 0.93 ± 0.02 | 21.11 ± 0.20 | 0.70 ± 0.11 | 10.60 ± 2.01 | 5.40 ± 0.02 |
SILY 140 | 1.54 ± 0.11a,b | 28.72 ± 0.23a,b | 0.82 ± 0.05a,b | 24.54 ± 0.34a,b | 3.38 ± 0.04a |
SILY 280 | 1.98 ± 0.02a,b | 31.76 ± 0.22a,b | 1.12 ± 0.05a,b | 30.20 ± 0.78a,b | 2.33 ± 0.03a,b |
DEX | 0.78 ± 0.03a | 12.78 ± 0.22a | 0.30 ± 0.05a | 6.65 ± 1.10a | 14.40 ± 0.06a |
DEX/SERT | 0.67 ± 0.01a,c | 13.67 ± 0.20a | 0.35 ± 0.01a,c | 6.92 ± 1.00c | 14.57 ± 0.16a |
DEX/SILY 140 | 0.98 ± 0.01c,d | 22.16 ± 0.10c,d | 0.56 ± 0.04a,c | 11.40 ± 1.23c,d | 9.65 ± 0.05a,c,d |
DEX/SILY 280 | 1.00 ± 0.12a,c,d | 27.20 ± 0.22a,c,d | 0.78 ± 0.03a,c,d | 12.45 ± 1.30c,d | 5.57 ± 0.01a,c,d |
DEX/SERT/SILY 140 | 0.82 ± 0.02a,c,d | 19.70 ± 0.10a,c,d | 0.75 ± 0.01c,d | 10.12 ± 1.01c,d | 4.98 ± 0.05a,c,d |
DEX/SERT/SILY 280 | 0.98 ± 0.02a,c,d | 21.21 ± 0.20c,d | 0.88 ± 0.03a,c,d | 11.32 ± 0.76c,d | 4.82 ± 0.02a,c,d |
- Citation: Onaolapo AY, Sulaiman H, Olofinnade AT, Onaolapo OJ. Antidepressant-like potential of silymarin and silymarin-sertraline combination in mice: Highlighting effects on behaviour, oxidative stress, and neuroinflammation. World J Pharmacol 2022; 11(3): 27-47
- URL: https://www.wjgnet.com/2220-3192/full/v11/i3/27.htm
- DOI: https://dx.doi.org/10.5497/wjp.v11.i3.27